Biotech & MedTech News
-
DIAGNOS Files FDA Pre-Submission for its CARA System: Strategic Entry into the U.S. Optometry Market with Support from ORA LLC
July 16, 2025 (Source) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A),…
-
Voyageur Pharmaceuticals Grants Deferred Share Units and Options and Accelerates Expiry Date of Warrants
July 14, 2025 (Source) — Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC: VYYRF) (“Voyageur” or the “Corporation”), a provider…
-
DIAGNOS Welcomes Veteran Optometrist Dr. Barry A. Ginsberg to its Scientific Advisory Board for the United States
June 25, 2025 (Source) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A),…
-
Voyageur Pharmaceuticals Signs LOI for Latin America Distribution Partnership Supporting Global Market Expansion
June 24, 2025 (Source) — Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) (“Voyageur”, or the “Company”), a Canadian public company…
-
Voyageur and Altillion Forge Landmark Alliance to Establish North America’s First Vertically Integrated Iodine Drug Supply Chain
June 23, 2025 (Source) — Voyageur Pharmaceuticals Ltd. (TSXV:VM) (“Voyageur” or the “Company”), a Canadian public company developing cost-effective…
-
DIAGNOS Welcomes Founder of National Vision Associates, Ed Weiner, to its Advisory Board for the United States
June 10, 2025 (Source) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A),…
-
Voyageur Enters Revenue Stage with First Commercial Sale of Barium Contrast Agents
June 4, 2025 (Source) — Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) (“Voyageur” or the “Company”), a radiology contrast…
-
DIAGNOS Welcomes Former White House Economic Adviser Dr. Tomas J. Philipson to its Advisory Board for the US Market
June 4, 2025 (Source) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A),…
-
DIAGNOS Announces the Engagement of Allele Capital Partners
May 23, 2025 (Source) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A),…
-
DIAGNOS Announces Amendment to Convertible Debentures
May 20, 2025 (Source) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A),…
